Trade Blueprint Medicines Corporation - BPMC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.64 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 93.92 |
| Open | 93.98 |
| 1-Year Change | 3.25% |
| Day's Range | 91.66 - 93.98 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 91.70 | -2.60 | -2.76% | 94.30 | 94.99 | 91.38 |
| Feb 20, 2025 | 93.92 | 0.87 | 0.93% | 93.05 | 96.44 | 92.67 |
| Feb 19, 2025 | 93.57 | 3.17 | 3.51% | 90.40 | 94.34 | 90.40 |
| Feb 18, 2025 | 92.32 | -1.58 | -1.68% | 93.90 | 94.64 | 91.44 |
| Feb 14, 2025 | 93.45 | -1.31 | -1.38% | 94.76 | 95.71 | 92.41 |
| Feb 13, 2025 | 94.95 | 0.05 | 0.05% | 94.90 | 99.22 | 94.34 |
| Feb 12, 2025 | 103.03 | 4.76 | 4.84% | 98.27 | 104.73 | 98.27 |
| Feb 11, 2025 | 101.08 | -0.79 | -0.78% | 101.87 | 103.54 | 100.68 |
| Feb 10, 2025 | 103.27 | -1.25 | -1.20% | 104.52 | 104.93 | 100.31 |
| Feb 7, 2025 | 104.90 | -3.61 | -3.33% | 108.51 | 110.16 | 103.85 |
| Feb 6, 2025 | 109.50 | -0.70 | -0.64% | 110.20 | 111.71 | 108.28 |
| Feb 5, 2025 | 109.66 | 0.59 | 0.54% | 109.07 | 114.99 | 109.07 |
| Feb 4, 2025 | 112.71 | 2.21 | 2.00% | 110.50 | 113.68 | 110.06 |
| Feb 3, 2025 | 111.45 | 2.42 | 2.22% | 109.03 | 112.45 | 107.91 |
| Jan 31, 2025 | 112.28 | -0.33 | -0.29% | 112.61 | 115.59 | 111.73 |
| Jan 30, 2025 | 113.22 | -1.69 | -1.47% | 114.91 | 115.08 | 112.16 |
| Jan 29, 2025 | 113.85 | 3.90 | 3.55% | 109.95 | 116.79 | 109.95 |
| Jan 28, 2025 | 114.44 | 1.58 | 1.40% | 112.86 | 114.95 | 112.06 |
| Jan 27, 2025 | 113.64 | 0.15 | 0.13% | 113.49 | 117.87 | 112.94 |
| Jan 24, 2025 | 114.68 | 2.20 | 1.96% | 112.48 | 117.17 | 112.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Blueprint Medicines Corporation Company profile
About Blueprint Medicines Corp
Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com